Transdermal Asenapine in Schizophrenia: A Systematic Review

References

• United Ststes Food and Drug Administration (USFDA). Press Announcements: FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder; 2009. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm177401.html. Accessed June 29 2020.
   Google Scholar
• Citrome L, Zeni CM, Correll CU. Patches: established and emerging transdermal treatments in psychiatry. J Clin Psychiatry. 2019;80(4):18nr12554. doi:10.4088/JCP.18nr12554.
   Web of Science ®Google Scholar
• Citrome L, Walling D, Zeni C, Komaroff M, Park A Efficacy and safety of an asenapine transdermal system (HP-3070) for treatment of adults with schizophrenia: a Phase 3 randomized, placebo-controlled, inpatient study. Presented at: Psych Congress 2019; October 3-6, 2019; San Diego, CA. Poster 122.
   Google Scholar
• Mohr P, Rietscher R, Eifler R, Bourquain O, inventors. LTS Lohmann Therapie-Systeme AG, Andernach, Germany, applicant. Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene. WO2018115010A1; 2018.
   Google Scholar
• Mohr P, Rietscher R, Eifler R, Bourquain O, inventors. LTS Lohmann Therapie-Systeme AG, Andernach, Germany, applicant. Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer. WO2019002204A1; 2019.
   Google Scholar
• Mohr P, Rietscher R, Eifler R, Bourquain O, inventors. LTS Lohmann Therapie-Systeme AG, Andernach, Germany, appli- cant. Transdermal therapeutic system containing asenapine. WO2018115001A1; 2018.
   Google Scholar
• Shreya AB, Managuli RS, Menon J, et al. Nano-transfersomal formulations for transdermal delivery of asenapine maleate: in vitro and in vivo performance evaluations. J Liposome Res. 2016;26(3):221–232. doi:10.3109/08982104.2015.1098659
   PubMed Web of Science ®Google Scholar
• Solomon WD; inventor. Transdermal Compositions of Asenapine for the Treatment of Psychiatric Disorders. WO2010127674A1. Copenhagen, Denmark: Sunin K/S; 2010.
   Google Scholar
• Suzuki M, Okutsu H, Yasukochi T, Takada Y; inventors. Assignee. Patch. US20170172981A1. Tosu-shi: Hisamitsu Pharmaceutical Co., Inc.; 2017.
   Google Scholar
• Suzuki M, Okutsu H, Yasukochi T, Takada Y; inventors. Assignee. Patch US20180360968A1. Tosu-shi, Japan: Hisamitsu Pharmaceutical Co., Inc; 2018.
   Google Scholar
• van de Wetering-krebbers SFM, Jacobs PL, Kemperman GJ, et al. Metabolism and excretion of asenapine in healthy male subjects. Drug Metab Dispos. 2011;39(4):580–590. doi:10.1124/dmd.110.036715
   PubMed Web of Science ®Google Scholar
• Lu D, Xie Q, Wu B. N-glucuronidation catalyzed by UGT1A4 and UGT2B10 in human liver microsomes: assay optimization and substrate identification. J Pharm Biomed Anal. 2017;145:692–703. doi:10.1016/j.jpba.2017.07.037
   PubMed Web of Science ®Google Scholar
• Reyad A, Asenapine: MR. Pharmacological aspects and role in psychiatric disorders. Psychiatr Danub. 2019;31(2):157–161. doi:10.24869/psyd.2019.157
   Web of Science ®Google Scholar
• Citrome L. Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014;10(6):893–903. doi:10.1517/17425255.2014.908185
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research (CDER). SAPHRIS® (asenapine) Sublingual Tablets, Chemistry Review(s) – access data FDA; NDA 22-117, 2009. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022117s000_ChemR.pdf. Accessed 20 March 2020.
   Google Scholar
• Hua S. Advances in nanoparticulate drug delivery approaches for sublingual and buccal administration. Front Pharmacol. 2019;10:1328. doi:10.3389/fphar.2019.01328
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, Watkins J. Prolactin elevations and the permeability glycoprotein. Prim Care Companion CNS Disord. 2019;21(3):18nr02412. doi:10.4088/PCC.18nr02412
   Google Scholar
• Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268. doi:10.1038/nbt.1504
   PubMed Web of Science ®Google Scholar
• Abruzzo A, Cerchiara T, Luppi B, Bigucci F. Transdermal delivery of antipsychotics: rationale and current status. CNS Drugs. 2019;33:849–865. doi:10.1007/s40263-019-00659-7
   PubMed Web of Science ®Google Scholar
• Kaminsky B, Bostwick J, Guthrie S. Alternative routes of administration of antidepressants and antipsychotic medications. Ann Pharmacother. 2015;49(7):808–817. doi:10.1177/1060028015583893
   PubMed Web of Science ®Google Scholar
• Secuado (asenapine) [prescribing information]. Miami, FL. Noven Therapeutics, LLC; 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212268s000lbl.pdf. Accessed May 15, 2020.
   Google Scholar
• de Greef R, Maloney A, Olsson-Gisleskog P, Schoemaker J, Panagides J. Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. AAPS J. 2011;13(1):121–130. doi:10.1208/s12248-010-9247-4
   Web of Science ®Google Scholar
• Food and Drug Administration. NDA/BLA Multi-disciplinary Review and Evaluation NDA 212268 Secuado (asenapine) transdermal system. 2018. Available from: https://www.fda.gov/media/124109/download. accessed April 3, 2020.
   Google Scholar
• McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11(7):673–686. doi:10.1111/j.1399-5618.2009.00748.x
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010;122(1–2):27–38. doi:10.1016/j.jad.2009.12.028
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology (Berl). 2016;233(14):2663–2674. doi:10.1007/s00213-016-4295-9
   PubMed Web of Science ®Google Scholar
• Landbloom R, Mackle M, Wu X, et al. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr. 2017;22(4):333–341. doi:10.1017/S1092852916000377
   Web of Science ®Google Scholar
• Shahid M, Walker GB, Zorn SH, Wong E. Asenapine: A novel psychopharmacological agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65–73. doi:10.1177/0269881107082944
   PubMed Web of Science ®Google Scholar
• Marazziti D, Piccini A, Baroni S, et al. Current trends on antipsychotics: focus on asenapine. Curr Medicinal Chem. 2019;23(21):2204–2216. doi:10.2174/0929867323666160525115014
   Web of Science ®Google Scholar
• Ghanbari R, El Mansari M, Shahid M, Blier P. Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, alpha2-adrenergic and D2 receptors in the rat brain. Eur Neuropsychopharmacol. 2009;19(3):177–187. doi:10.1016/j.euroneuro.2008.11.001
   PubMed Web of Science ®Google Scholar
• Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1- and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine—relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538–544. doi:10.1001/archpsyc.1992.01820070032005
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, McKenzie C. The dopamine D4/D2 receptor antagonist affinity ratio as a predictor of anti-aggression medication efficacy. Med Hypotheses. 2013;80(5):530–533. doi:10.1016/j.mehy.2012.10.014
   Web of Science ®Google Scholar
• Pratts M, Citrome L, Grant W, Leso L, Opler LA. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand. 2014;130(1):61–68. doi:10.1111/acps.12262
   PubMed Web of Science ®Google Scholar
• Amon JS, Johnson SB, El-Mallakh RS. Asenapine for the control of physical aggression: a prospective naturalist pilot study. Psychopharmacol Bull. 2017;47(1):27–32.
   PubMedGoogle Scholar
• Bozzatello P, Rocca P, Uscinska M, Bellino S. Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: an open-label randomized controlled trial. CNS Drugs. 2017;31(9):809–819. doi:10.1007/s40263-017-0458-4
   PubMed Web of Science ®Google Scholar
• Citrome L, Landbloom R, Chang CT, Earley W. Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder. Neuropsychiatr Dis Treat. 2017;13:2955–2963. doi:10.2147/NDT.S149376
   PubMed Web of Science ®Google Scholar
• Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG. 5-HT7 receptor inhibition and inactivation induce antidepressant-like behavior and sleep pattern. Biol Psychiatry. 2005;58:831–837. doi:10.1016/j.biopsych.2005.05.012
   PubMed Web of Science ®Google Scholar
• Wesolowska A, Nikiforuk A, Stachowicz K, Tatarczynska E. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology. 2006;51:578–586. doi:10.1016/j.neuropharm.2006.04.017
   PubMed Web of Science ®Google Scholar
• Wang H, Xiao L, Wang HL, Wang GH. Efficacy and safety of lurasidone versus placebo as adjunctive to mood stabilizers in bipolar I depression: A meta-analysis. J Affect Disord. 2020;264:227–233. doi:10.1016/j.jad.2019.11.031
   Web of Science ®Google Scholar
• El-Mallakh RS, Nuss S, Gao D, et al. Asenapine in the treatment of bipolar depression. Psychopharmacol Bull. 2020;50(1):8–18.
   PubMedGoogle Scholar
• Fox L, Gerber M, Plessis JD, Hamman J. Transdermal drug delivery enhancement by compounds of natural origin. Molecules. 2011;16:10507–10540. doi:10.3390/molecules161210507
   Web of Science ®Google Scholar
• Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Sitinchcomb AL. Challenges and opportunities in dermal/transdermal delivery. Ther Deliv. 2010;1:109–131. doi:10.4155/tde.10.16
   PubMedGoogle Scholar
• Borovinskaya M, Robert B, Plakogiannis FM. Evaluation of in vitro percutaneous absorption of olanzapine and fluoxetine HCl: enhancement properties of olanzapine. Drug Dev Ind Pharm. 2012;38(2):227–234. doi:10.3109/03639045.2011.597765
   PubMed Web of Science ®Google Scholar
• Ng KW. Penetration enhancement of topical formulations. Pharmaceutics. 2018;10(2):E51. doi:10.3390/pharmaceutics10020051
   Web of Science ®Google Scholar
• Tenjin T, Miyamoto S, Ninomiya Y, et al. Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2013;9:587–594. doi:10.2147/NDT.S34433
   PubMed Web of Science ®Google Scholar
• Sumitomo Dainippon Pharma Co., Ltd., Long-term study of DSP- 5423P in Patients with Schizophrenia. ClinicalTrials.gov identifier NCT02335658; 2014. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02335658?term=DSP5423P&cntry=JP&rank=1. Accessed 15 May 2020..
   Google Scholar
• Sonobe A, Yasukochi T, Takada Y; inventors. Assignee. Patch US20180289631A1. Tosu-shi, Japan: Hisamitsu Pharmaceutical Co., Inc.; 2018.
   Google Scholar
• Minassian A, Young J. Evaluation of the clinical efficacy of asenapine in schizophrenia. Expert Opin Pharmacother. 2011;11(12):2107–2115. doi:10.1517/14656566.2010.506188
   Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi:10.1093/schbul/13.2.261
   PubMed Web of Science ®Google Scholar
• Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenia. Psychiatry Res. 1988;23(1):99–110. doi:10.1016/0165-1781(88)90038-8
   PubMed Web of Science ®Google Scholar
• Østergaard SD, Foldager L, Mors O, Bech P, Correll CU. The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. Acta Psychiatr Scand. 2018;138(5):420–431. doi:10.1111/acps.12952
   PubMed Web of Science ®Google Scholar
• Citrome L, Walling D, Zeni C, Komaroff M, Park A Efficacy and safety of an asenapine transdermal system (Asenapine Transdermal System, HP-3070) in the treatment of adults with schizophrenia: a Phase 3 randomized, double-blind, placebo-controlled, 6-week inpatient study. Presented at the 57th Annual Meeting of the American College of Neuropsychopharmacology, December 9–13, 2018, Hollywood, Florida
   Google Scholar
• Citrome L, Walling D, Zeni C, Komaroff M, Park A HP-3070 asenapine transdermal system in adults with schizophrenia: categorical response and clinical relevance as assessed in a Phase 3 RCT. Presented at the Annual American Psychiatric Association Meeting, May 18–22, 2019, San Francisco, CA, USA
   Google Scholar
• Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract. 2009;63(12):1762–1784. doi:10.1111/j.1742-1241.2009.02228.x
   PubMed Web of Science ®Google Scholar
• Leucht S, Barabássy Á, Laszlovszky I, et al. Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia. Neuropsychopharmacology. 2019;44(9):1589–1596. doi:10.1038/s41386-019-0363-2
   PubMed Web of Science ®Google Scholar
• Durgam S, Landbloom RP, Mackle M, Wu X, Mathews M, Nasrallah HA. Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study. Neuropsychiatr Dis Treat. 2017;13:2021–2035. doi:10.2147/NDT.S130211
   Web of Science ®Google Scholar
• Worthington MA, El-Mallakh RS. A naturalistic retrospective review of weight gain in bipolar patients treated with second generation antipsychotics. J Clin Psychopharmacol. 2015;35(2):192–193. doi:10.1097/JCP.0000000000000271
   Web of Science ®Google Scholar
• Sweet G Jr., Washington NB, Brahm NC. An ulcerated mouth lesion following one dose of sublingual asenapine. Ment Health Clin. 2015;5(4):180–183. doi:10.9740/mhc.2015.07.180
   Google Scholar